Search
A journey to hematology – a dream come true
YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true
by Dr.
Help disseminate IVDR Questionnaire - Share with diagnostic laboratories in your network
The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.
Read moreHARMONY: Big data for better and faster treatment
HARMONY Alliance: A European Network of Excellence for Big Data in Hematology - Enabling Better and Faster Treatment based on Big Data technologies
Despite data being a key driver for modern evidence-based medicine, we have been struggling with the same challenge for…
EHA Awards 2011 at the 16th Congress of EHA in London
Bob Löwenberg will be the fourth recipient of the Jean Bernard Lifetime Achievement Award which was presented for the first time at the 13th Annual Congress in Copenhagen.
Read moreBurnouts: when caregivers become patients
Author: Côme Bommier (Young EHA Ambassador)
Affiliations: Hôpital St-Louis (Paris, France) & Mayo Clinic (Rochester MN, USA)
A survey will be released in September to further map burnout
among hematology professionals in Europe.
Call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition
Dear GoCART community,
With more than 5,000 CAR-T infusions registered in the EBMT Registry, EBMT and EHA are proud to announce the third call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition.
ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
Presentations
EHA-MSH Hematology Tutorial
Session 1: Basic Principles of Hodgkin Lymphoma
Lecture: MJ Kersten (Not available)
Clinical Case: PL Low (Not available)
Self-assessment case: MJ Kersten (Not available)
Session 2: Histopathology and Diagnosis
Lecture: MA Piris (here)
Clinical Case: CC Liong (here)
Self-assessment case: MA Piris (here)
Session 3: Treatment of Newly Diagnosed Hodgkin Lymphoma
Lecture: A Czyż (here)
Clinical…
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- »